Article abstract-In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed. NEUROLOGY 2001;56:97-99 E. Ciafaloni, MD; J.M. Massey, MD; B. Tucker-Lipscomb, RN, BSN, APN; and D.B. Sanders, MD Mycophenolate mofetil (MM) (CellCept, Roche Laboratories, Nutley, NJ) is a novel and potent immunosuppressive agent. It blocks purine synthesis in activated T and B lymphocytes and selectively inhibits their proliferation while leaving other cell lines intact.
Patients and methods.
This open-label pilot trial investigated the short-term efficacy and safety of MM in patients with MG. Patients between the ages of 18 and 80 years, with acquired MG diagnosed according to accepted clinical, electrophysiologic, and pharmacologic criteria 7 who had or had not undergone thymectomy and who had or did not have elevated acetylcholine receptor antibodies (AChR Ab) were eligible for the study. Two groups of patients were studied: 1) patients with refractory MG defined by a quantified MG (QMG) 8 score of at least 10 and a manual muscle test (MMT) score (figure) of at least 5, despite treatment with corticosteroids and azathioprine for at least 2 years or cyclosporine for at least 1 year; and 2) patients taking corticosteroids as sole therapy for at least 8 months and requiring additional immunosuppression to heighten the clinical improvement or to reduce the corticosteroid side effects. No plasmapheresis, IV immunoglobulin treatment, or change in medication dose was permitted for 3 months before enrollment. Anticholinesterase medications were continued, and examinations were performed 4 hours after the most recent dose. MM was administered in an oral dose of 1 g every 12 hours for 6 months, and clinic visits were performed every 2 months. The primary measure of efficacy was a reduction of at least 3 points in the QMG and at least 2 points in the MMT, or a reduction of at least 50% in corticosteroid dose for at least 3 months without worsening of the QMG and MMT scores. An activities of daily living (ADL) 9 questionnaire was also administered by phone every week for the first month and at clinic visits every 2 months thereafter, and was considered a secondary test of efficacy. The QMG and ADL scores have previously been validated in assessing MG. 8, 9 MMT is a physician-applied scoring system of strength in muscles that are typically affected in MG (see the figure). All QMG tests were performed by the same nurse (B.T.L.) and MMT by one of the two senior investigators (J.M.M., D.B.S.). AChR Ab were measured at baseline and at the end of 6 months at the Mayo Medical Laboratory, Rochester, MN. Single-fiber electromyography (EMG) of the extensor digitorum communis or frontalis muscle was performed in the Duke University Medical Center EMG laboratory by the same examiner (J.M.M. or D.B.S.) at baseline and at the end of 6 months. Safety was assessed by physical and laboratory examinations, evaluation of vital signs, and monitoring of adverse reactions.
Results. Twelve patients entered the study (table 1) (seven men, five women; mean age, 56 years). All patients completed the study. Eleven patients had had thymectomy 7 months to 42 years earlier (mean, 16 years). The duration of MG varied from 7 months to 47 years (mean, 19 years). Seven patients met the criteria for group 1 (Patients 1 through 7; see table 1) and five for group 2 (Patients 8 through 12; see table 1). Eight patients (67%) improved, six by QMG and MMT scores (Patients 2, 3, 5, 6, 8, and 11; table 2), and two by reduction of corticosteroid dose (Patients 9 and 10; see table 2). These two patients also had some improvement of QMG and MMT scores. One patient worsened (Patient 12; see table 2), two improved only by QMG score (6 and 5 points), and one only by MMT score (10 points), and therefore were considered un-changed. Wilcoxon signed-rank sum analysis of all study patients showed improvement in MMT, QMG, and ADL scores at 6 months compared with baseline (p Ͻ 0.023, 0.001, and 0.004). Improvement in the ADL scores was seen as early as 2 weeks after MM treatment was begun, and improvement was seen in all responders at the first follow-up visit (2 months). In eight of 10 patients, the corticosteroid dose was reduced. Mestinon was discontinued in two and decreased in four of eight patients. Cyclosporine was decreased by 50% in two of three patients. Wilcoxon signed-rank sum analysis of AchR-binding Ab levels showed a reduction at 6 months compared with baseline (p Ͻ 0.016). The mean group jitter value was unchanged (82.2 s at baseline and 82.0 s at 6 months), and the mean group percentage of potential pairs with blocking was insignificantly decreased (28% at baseline and 25% at 6 months). No major side effects were observed. No diarrhea was reported. Two patients reported mild hand tremors that resolved after the first week. The hemoglobin value was decreased in two patients (2.6 and 1.9 g/dL). One of these patients was found to have iron deficiency as the cause of her anemia. Seven of the improved patients elected to continue taking MM at the end of the study, and one did not because of financial reasons.
Discussion.
In this open-label pilot study, MM appeared to be effective as adjunctive therapy in the treatment of refractory and steroid-dependent MG. All seven patients with refractory MG had reached a plateau of clinical improvement after receiving steroids and azathioprine or cyclosporine for an adequate period, but still had significant weakness and subjective MG symptoms before MM treatment was begun. They were also still experiencing exacerbations and had previously been unable to reduce their medications without worsening. Five of them experienced significant improvement and were able to decrease their steroid dose while taking MM; two decreased their cyclosporine dose by 50%. Our data also suggest a steroid-sparing effect of MM, because eight of 11 patients taking prednisone at the time MM treatment was begun were able to decrease the prednisone dose without worsening.
In all eight patients who improved, symptomatic improvement started early, between 2 weeks and 2 months, and persisted throughout the 6 months. There were no major side effects observed, and all patients were able to tolerate the drug. The safe side effect profile and the rapid onset of therapeutic effect, if confirmed in the future, would make MM a very attractive alternative to other currently available immunosuppressants for MG. All our patients were receiving other forms of immunosuppression at the time MM treatment was begun; therefore, the potential role of MM as sole therapy remains to be investigated. Larger, prospective, randomized, controlled trials are needed to confirm our results and to assess long-term efficacy and safety of MM in MG. 
